NeuroScientific Biopharmaceuticals (NSB) Investor Update summary

Strategic evolution and technology acquisition

• Acquired the patented STEMsmart stem cell platform, pivoting focus to address unmet needs in inflammatory, degenerative, and autoimmune conditions, with initial emphasis on Crohn's disease.

• New leadership and expertise brought in, including a new CEO and Chief Medical Officer, to drive the new strategy.

• Early-stage clinical data supports efficacy, with a 78% response rate and over 50% remission in refractory Crohn's patients from previous trials.

Clinical development and special access program

• Special access program launched in Australia for fistulizing Crohn's disease patients with no other treatment options; first four patients treated, aiming for up to 12.

• Results from the first four patients expected in January, with full program results by mid-2026.

• Data from this program will inform the design and execution of a phase two clinical trial in Australia and the US.

Manufacturing and partnerships

• Manufacturing tech transfer to Qiagen, a leading contract manufacturer, to scale production and de-risk supply for clinical trials and commercialization.

• Qiagen's experience with TGA and international standards strengthens regulatory and supply chain reliability.